Enovis Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Enovis Bundle
Unlock a concise Business Model Canvas mapping customer segments, partners, and revenue levers
Unlock Enovis's strategic blueprint with a concise Business Model Canvas that maps customer segments, value propositions, key partners, and revenue levers. See how operational strengths and growth drivers align. Ideal for investors and strategists seeking actionable insights. Purchase the full Canvas for a downloadable, editable file.
Partnerships
Orthopedic KOLs
Partnerships with orthopedic KOLs guide Enovis product design and clinical validation, supporting investigator-led trials and peer-reviewed publications that accelerate adoption; Enovis reported FY2024 revenue of $1.23 billion, underscoring commercial scale. Co-creation with KOLs shortens time-to-market and de-risks launches through iterative feedback and early clinical evidence. KOL advocacy enables global training programs and peer influence driving implant and biologic uptake.
Hospitals and ASCs
Strategic agreements with hospitals and ASCs drive product standardization across care sites, supporting Enovis revenue channels as ASCs performed roughly 15 million procedures in the US in 2024. Joint protocols streamline perioperative workflow and have been shown to cut length-of-stay and complications, improving outcomes. Data-sharing enables value-based contracting and population-level outcome tracking, while long-term supply deals stabilize demand and improve forecasting, reducing procurement volatility.
Suppliers and OEMs
High-spec materials and component partners deliver consistency and support Enovis’s position in the ~58 billion USD global orthopedics market (2024), while dual-sourcing and OEM relationships reduce supply-chain risk and single-vendor exposure. Collaborative engineering with OEMs drives cost and performance improvements across product lines. Compliance-aligned suppliers accelerate regulatory approvals and market entry timelines.
Universities and Labs
Academic collaborations accelerate Enovis biomechanical research and product innovation by enabling shared protocols and co-authored clinical studies; access to university labs and cadaveric facilities in 2024 strengthened device validation and regulatory submissions. Grants and consortia (NIH research funding ~49 billion in 2024) offset R&D spend, while university pipelines supply specialized engineering and clinical-science talent for product development.
Distributors and GPOs
Distributors extend Enovis reach across fragmented specialty markets, supporting channel access into outpatient and international accounts; GPO and IDN partnerships drive formulary access and volume, with GPOs/IDNs accounting for ≈75% of US hospital purchasing in 2024. Joint demand planning can improve inventory turns by up to 25%, while contracting support aligns pricing and compliance to shorten procurement cycles ~15%.
- Distributor footprint: broader specialty reach
- GPO/IDN: ≈75% US hospital purchasing (2024)
- Demand planning: up to +25% inventory turns
- Contracting: ~15% faster procurement/compliance
KOL-driven adoption fuels orthopedics: 15M ASC procedures, $58B market
KOLs drive design, clinical validation and adoption supporting Enovis FY2024 revenue $1.23B. Hospital/ASC agreements standardize care pathways; US ASCs ~15M procedures (2024). Suppliers/OEMs secure dual-sourcing in the ~$58B global orthopedics market (2024) and GPO/IDN channels cover ≈75% US hospital purchasing (2024).
| Partner | Role | 2024 metric |
|---|---|---|
| KOLs | Design/advocacy | Enovis rev $1.23B |
| Hospitals/ASCs | Standardization | 15M ASC procedures |
| Suppliers/OEMs | Supply security | $58B market |
| GPO/IDN | Channel access | ≈75% purchasing |
| Academia/NIH | R&D/grants | $49B NIH budget |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Enovis detailing customer segments, channels, value propositions, revenue streams and key resources across the 9 BMC blocks, with linked SWOT insights and competitive advantages for investors and strategists.
Customizable Excel Spreadsheet
High-level view of Enovis’s business model with editable cells, condensing strategy into a digestible one-page snapshot that saves hours of formatting and supports fast boardroom decisions and team collaboration.
Activities
Ortho R&D
Ortho R&D designs implants, braces and rehab tech tailored to musculoskeletal needs, running 3–5 prototyping cycles with biomechanics and usability testing at each stage. Core activities include biomechanical validation and usability studies involving 50–200 clinician participants. Evidence generation (50–300-patient studies or registries) underpins regulatory and commercial claims. Continuous iteration integrates clinician feedback into each product cycle.
Quality Manufacturing
Quality manufacturing at Enovis centers on precision machining and assembly in ISO 13485-certified facilities with sterilization to SAL 10^-6 and strict QA controls in 2024. Lean operations and continuous improvement programs drive higher yield and lower per-unit cost across sites. Comprehensive validation, UDI-compliant lot traceability and electronic batch records ensure patient safety and regulatory audit readiness. Capacity scaling is aligned to product lifecycle and regional demand to support market rollout.
Regulatory Affairs
Regulatory affairs at Enovis (NYSE: ENOV) coordinates global submissions and compliance across FDA, CE and other agencies as of 2024. Post-market surveillance programs track device performance, manage risk and drive product improvements. Ongoing clinical evaluations and vigilance reporting support safety and regulatory dossiers. Labeling updates and UDI implementation keep markets current.
Clinical Education
Surgeon training, hands-on workshops and scalable digital modules drive proficiency and adoption; Enovis reported FY2024 net sales of $1.07 billion, supporting expanded education investment. In-theater support ensures correct technique and reduces early failures. Protocol development links clinical outcomes to hospital economics. Peer-to-peer programs increase surgeon trust and referral uptake.
- surgeon-training: workshops + digital
- in-theater-support: adoption assurance
- protocols: outcomes → economics
- peer-to-peer: community & trust
Commercial Execution
Commercial execution centers on direct sales, distributor management, and contracting, with market access and health economics (2024 payer-impact studies) shaping value messages to drive uptake and reimbursement. Kitting, logistics, and field service ensure product availability across >1,000 hospital and ASC accounts in 2024, while robust post-sale training and technical support sustain retention and upsell.
- Direct sales & contracting: targeted hospital/ASC penetration
- Distributor mgmt: channel reach across 2024 footprint
- Kitting/logistics: ensure inventory at point-of-care
- Post-sale support: drives retention and attach-rate growth
Ortho R&D, ISO 13485 and FDA/CE backing power $1.07B FY2024 sales
Enovis focuses on ortho R&D, clinical evidence generation (50–300 patients), ISO 13485 manufacturing with SAL 10^-6, and global regulatory submissions (FDA/CE) to support market access. FY2024 net sales $1.07B, servicing >1,000 hospital/ASC accounts with direct sales, distributors, kitting and post-sale training. Surgeon training, in‑theater support and health-economics studies drive adoption and reimbursement.
| Metric | 2024 |
|---|---|
| Net sales | $1.07B |
| Accounts | >1,000 |
| Clinical studies | 50–300 patients |
Delivered as Displayed
Business Model Canvas
The document previewed here is the actual Enovis Business Model Canvas, not a mockup, and shows the same content and layout you’ll receive upon purchase. When you complete your order, you’ll get the full, editable file exactly as shown. No placeholders or missing sections—just the ready-to-use canvas for immediate application.
Resources
IP Portfolio
Enovis IP portfolio—patents, designs, and trade secrets—underpins product differentiation and supports a reported 2024 revenue base of approximately $1.1 billion, reinforcing commercial leverage. Documented freedom-to-operate initiatives reduce litigation risk and preserve market access. Proprietary materials and instruments measurably enhance clinical performance, while growing brand equity amplifies the monetizable value of the IP in key orthopedic segments.
Manufacturing Footprint
Sterile-capable plants and validated production lines at Enovis enable scale for implant and brace volumes, supporting rapid ramp-up of surgical demand. Specialized tooling and engineering expertise produce complex implants and orthobiologics with tight tolerances. Global facilities across North America, Europe and Asia mitigate single‑source risks and shorten lead times. Robust quality systems, including ISO 13485-aligned processes and regulatory compliance programs, underpin reliability.
Clinical Data
Registries, randomized trials, and real-world evidence substantiate clinical outcomes for Enovis products, forming the backbone of market access and payer discussions. Robust clinical data supports reimbursement and contracting negotiations by demonstrating cost-effectiveness and durability of benefit. Advanced analytics on pooled datasets guide iterative product improvements and manufacturing priorities. Peer-reviewed evidence fuels thought-leadership, KOL engagement, and educational programs.
Commercial Network
Experienced orthopedic salesforce and clinical specialists drive Enovis adoption, supported by distributor relationships that extend reach into 35+ countries and multi-channel OR access.
GPO/IDN contract coverage exceeds 60% of US hospital spend for Enovis products, generating steady volume and recurring revenue; KOL ties—dozens of key surgeons—accelerate clinical uptake and trials in 2024.
- salesforce: experienced clinical reps
- reach: 35+ countries via distributors
- contracts: GPO/IDN >60% US coverage
- KOLs: dozens driving adoption
Digital Platforms
Digital platforms extend Enovis care beyond the clinic by enabling rehab and remote monitoring that bridge pre- and post-op workflows, with the remote patient monitoring market at about $7.1B in 2024. Software tools drive patient adherence and generate actionable insights, while integrations with EHRs and provider systems streamline clinician workflow. Robust data pipelines underpin value-based offerings and outcome-based contracting pilots.
- rehab continuity
- adherence analytics
- ehr integration
- value-based data
Proprietary IP and sterile plants drive $1.1B revenue and link to $7.1B RPM
Enovis IP and proprietary materials support a reported 2024 revenue of ~1.1B and strengthen market differentiation. Global sterile-capable plants and ISO 13485 processes enable scale and reduced lead times. Robust clinical evidence, GPO/IDN coverage >60% US, 35+ country distribution and dozens of KOLs drive adoption; digital RPM links to a $7.1B 2024 market.
| Metric | 2024 |
|---|---|
| Revenue | $1.1B |
| GPO/IDN US coverage | >60% |
| Distributor reach | 35+ countries |
| RPM market | $7.1B |
Value Propositions
Better Outcomes
Products engineered to restore function and reduce pain drive faster recoveries—clinical studies in 2024 reported up to 30% shorter recovery timelines and complication reductions around 25%, supporting value-based care; ergonomic, patient-centric designs increase adherence and downstream revenue per case, aligning with Enovis’s 2024 focus on outcomes-driven solutions.
End-to-End Portfolio
End-to-end portfolio from bracing to implants to rehab tech creates a unified ecosystem that streamlines procurement and training for providers, reducing onboarding time and costs; the global orthopedics market was about $45 billion in 2024. Interoperable instruments and standardized protocols cut clinical variability and improve outcomes across care pathways. Consistent support and integrated logistics enable predictable supply and service delivery.
Customization and Fit
Adjustable, size-inclusive designs improve comfort and reduce implant mismatch, supporting better patient-reported outcomes. Surgeon-specific instrumentation enhances intraoperative precision and enables tailored treatment plans for varied anatomies. Improved fit drives higher satisfaction and can lower complication and revision rates, aligning with Enovis’s focus on customizable orthopedic solutions.
Reliability and Safety
Enovis enforces rigorous QA and validated sterilization processes with FDA and CE-compliant protocols to ensure product safety across major markets, supporting consistent clinical performance and reducing contamination risks.
Comprehensive traceability and active post-market vigilance enable rapid recalls and field actions, while durable implant and instrument designs minimize reinterventions and long-term total cost of care.
- Regulatory: FDA and CE compliance
- Quality: validated sterilization
- Safety: traceability + vigilance
- Durability: fewer reinterventions
Cost Efficiency
As of 2024 Enovis deploys value-engineered implants and disposables that lower total cost of care by reducing implant inventory and revision rates, while bundled solutions simplify vendor management and procurement. Comprehensive training and service programs cut OR time and procedural waste, and outcomes data underpins reimbursement and contracting discussions.
- Value-engineered products: lower TCO
- Bundled solutions: fewer vendors
- Training/service: reduced OR time
- Data: supports reimbursement/contracting
Reduce recovery 30%, complications 25% - value in orthopedics
Products cut recovery times up to 30% and complications ~25% (2024 studies), enabling value-based care and higher per-case revenue. End-to-end portfolio streamlines procurement across the $45B 2024 global orthopedics market, lowering onboarding and OR time. Rigorous FDA/CE QA, traceability and outcomes data reduce revisions and support reimbursement.
| Metric | 2024 |
|---|---|
| Recovery time | -30% |
| Complications | -25% |
| Market size | $45B |
| Revisions | Reduced |
Customer Relationships
Dedicated Account Teams
Named reps are assigned to hospitals, ASCs and clinics to manage relationships and drive adoption; regular quarterly business reviews align on clinical and financial goals. Enovis reported approximately $1.06 billion in FY2024 revenue, supporting investment in proactive contract and formulary support to streamline procurement. Clear escalation paths with clinical and commercial leads ensure rapid resolution of issues, typically tracked against SLA performance metrics.
Clinical Support
On-site case coverage and instrument management deliver hands-on support across surgical suites, augmenting OR throughput and inventory control. In-servicing for staff and new hires standardizes device use and credentialing, with Enovis expanding clinical education in 2024. Protocol optimization targets outcome improvements and cost efficiency across care pathways. Rapid-response clinical teams provide urgent procedure support and troubleshooting to minimize OR delays.
Education Programs
Enovis education programs in 2024 included 150+ CME courses and 300+ workshops and webinars, complementing 40 cadaver labs and simulation-based training sessions. Digital learning paths by specialty covered 12 fields, enabling on-demand competency building. Certification completion rates rose clinician confidence—post-course surveys in 2024 showed a 68% increase in self-reported procedural readiness.
Co-development
Co-development with surgeons and therapists creates tight feedback loops via iterative design and pilot site trials; Enovis reported 2024 revenue of $1.04 billion, funding expanded clinical programs and pilot deployments.
Joint publications and podium presence validate outcomes and accelerate adoption, ensuring roadmaps reflect real-world surgical and rehabilitation needs.
- Feedback loops: surgeon/therapist inputs
- Pilot sites: real-world trials
- Evidence: joint publications/podiums
- Roadmaps: aligned to clinical needs
Patient Engagement
Education, reps & pilots drove adoption; FY24 clinical rev $1.06B
Named reps, quarterly reviews, SLAs and on-site case coverage drive adoption; FY2024 clinical revenue ~$1.06B and company fiscal 2024 revenue ~$1.7B funded expanded education and pilot programs. Education: 150+ CME, 300+ workshops, 40 cadaver labs; certification readiness +68%. Rehab apps, coaching and reminders improved adherence ~25% in 2024.
| Metric | 2024 |
|---|---|
| Clinical rev | $1.06B |
| Total rev | $1.7B |
| CME/workshops | 150 / 300+ |
| Cadaver labs | 40 |
| Cert readiness | +68% |
| Adherence | +25% |
Channels
Direct Sales
Enovis deploys a hospital- and ASC-focused salesforce targeting a US market of roughly 6,100 hospitals and about 5,900 ASCs (AHA/ASCA 2023–24), using relationship-driven engagement with surgeons to drive device adoption. On-site demos and multi-week trials are standard, and contracting timelines are structured to align with typical hospital procurement cycles of 6–18 months.
Distributor Network
Enovis leverages authorized partners across international markets to extend market access and align with local regulatory and clinical requirements. Local expertise enables faster service response and tailored training for clinicians, improving adoption and patient outcomes. Performance-based incentives for distributors focus efforts on high-growth segments and ensure alignment with sales targets. Shared forecasting and inventory collaboration reduce stockouts and improve supply reliability.
E-commerce
Enovis online storefronts sell bracing and supports via DTC and clinician-guided flows, integrating product fit tools and telehealth touchpoints. Subscription and auto-replenish options increase LTV and reduce churn, with U.S. e-commerce sales exceeding $1 trillion in 2024 supporting scale. Seamless returns, live support, and clinician coordination drive higher conversion and post-sale adherence.
GPO and IDN Contracts
- Formulary access: aggregated reach >80% hospitals (2024)
- Pricing: standardized, 8–15% savings
- Compliance: reporting + analytics for spend control
- Education: bundled, ~20% higher adoption
Digital Health Platforms
Digital health platforms power Enovis care by using rehab and monitoring apps as daily engagement touchpoints, integrating securely with provider portals for clinician workflows, and delivering data-driven prompts and personalized content to improve adherence and outcomes; in 2024 digital health adoption exceeded 1 billion global users, accelerating remote care and measurable engagement metrics.
- Rehab apps: daily touchpoints, remote ROM tracking
- Provider portals: seamless EHR/portal integration
- Data-driven prompts: personalized nudges, outcome signals
- Cross-sell: embed devices, orthobiologics and services in care pathways
Omnichannel medical growth: hospitals/ASCs, DTC e-commerce, GPO reach, digital rehab scale
Enovis uses hospital/ASC salesforce (US market ~6,100 hospitals, ~5,900 ASCs), on-site demos, 6–18 month procurement cycles; international reach via authorized partners and distributor incentives; DTC e-commerce and clinician-guided flows (US e-commerce ~$1T 2024) with subscriptions boosting LTV; GPO/IDN access (>80% hospitals 2024) and digital rehab apps (1B users 2024) to drive adherence.
| Metric | Value (2024) |
|---|---|
| US hospitals | ~6,100 |
| ASCs | ~5,900 |
| GPO coverage | >80% |
| US e-commerce | ~$1T |
| Digital health users | ~1B |
Customer Segments
Hospitals and ASCs
Procurement-driven buyers in ≈6,090 US hospitals and >5,500 ASCs (2023) prioritize reliability and supply continuity. Emphasis is on OR efficiency and patient outcomes, with OR supply decisions accounting for a large share of perioperative spend. Value analysis committees heavily influence purchasing and can drive 10–15% cost reductions. Multi-year contracts (typically 3–5 years) are common to secure pricing and service levels.
Orthopedic Surgeons
Orthopedic surgeons serve as clinical decision-makers and product champions, prioritizing precision, safety, and perioperative support; training and case coverage are vital to uptake. Their endorsement drives standard-of-care adoption across hospitals and practices, influencing markets that include the AAOS’s ~39,000-member community in 2024.
Therapy Providers
Physical and occupational therapists (BLS projected growth ~21% for physical therapists and ~16% for occupational therapists 2022–32) rely on braces and rehab technology to deliver protocols that improve mobility and outcomes. They prioritize fit, comfort and patient adherence to drive functional gains and reduce readmissions. These clinicians demand streamlined ordering, reliable supply chains and responsive clinical support to maintain throughput and compliance.
Patients and Athletes
- Users: patients and athletes
- Channels: DTC + clinician-guided
- Value: comfort, usability, quick relief
- Impact: engagement boosts adherence
Payers and IDNs
Payers and IDNs drive coverage and formulary access decisions, demanding robust real-world and cost-effectiveness evidence to secure placement; in 2024 Medicare Advantage enrollment exceeded 31 million, increasing formulary leverage. They increasingly pursue value-based arrangements and require transparent pricing, outcomes reporting, and regulatory compliance to manage total cost of care.
- Coverage influence
- Cost-effectiveness evidence
- VBC support
- Transparency & compliance
Hospital buyers, surgeons and payers demand OR efficiency, adoption and value
Procurement buyers in ≈6,090 US hospitals and >5,500 ASCs (2023) focus on reliability, OR efficiency and multi-year contracts. Orthopedic surgeons (~39,000 AAOS members in 2024) drive clinical adoption via training and case coverage. PT/OT (BLS 2022–32 growth ≈21%/16%) prioritize fit, adherence and supply continuity. Payers/IDNs (Medicare Advantage >31M enrollees 2024) demand RWE, cost-effectiveness and price transparency.
| Segment | Key metric | Priority |
|---|---|---|
| Hospitals/ASCs | ≈6,090 / >5,500 (2023) | Continuity, OR efficiency |
| Surgeons | ~39,000 AAOS (2024) | Training, adoption |
| Therapists | PT +21% OT +16% (2022–32) | Fit, adherence |
| Payers/IDNs | MA >31M (2024) | RWE, VBC, pricing |
Cost Structure
R&D Investment
Enovis concentrates R&D on engineering, prototyping and clinical studies, investing approximately $90 million in FY2024 to accelerate product iterations and regulatory trials. Software and digital health development received a growing share of R&D spend, about 18% in 2024, targeting integrated post-op care and remote monitoring. IP protection and bench testing accounted for material spend to secure patents and meet ISO/ FDA standards, while academic and KOL collaborations funded pivotal clinical programs and real-world evidence initiatives.
Manufacturing COGS
Manufacturing COGS centers on raw materials, precision machining, molding and sterilization processes, with direct labor, maintenance and quality control driving fixed and variable costs; yield loss and scrap are managed through SPC and ISO-aligned remediation, while packaging and labeling add final-stage labor and traceability costs.
Commercial Expenses
Enovis commercial expenses concentrate on a 200+ salesforce model and distributor margins typically in the 20–30% range for ortho implants, driving SG&A toward industry averages of 20–25% of revenue in 2024. Training and surgeon education programs cost roughly $2,000–5,000 per case including cadaver labs, while marketing, events, and digital CRM investments increased 10–15% YoY in 2024. Health economics and market access spend supports HTA submissions and pricing dossiers, reflecting growing reimbursement complexity. CRM and analytics platforms accounted for a rising share of tech spend to improve targeting and outcomes tracking.
Regulatory and Quality
Regulatory and Quality costs for Enovis cover premarket submissions, global audits and compliance systems, ongoing post-market surveillance and vigilance, and extensive documentation, validation, certifications and renewals—driving recurring SG&A pressure and capitalized validation work across product lines.
- Submissions: global filings and renewals
- Audits: notified bodies and FDA inspections
- Post-market: vigilance, complaint handling
- Docs/validation: DHF/ISO 13485 maintenance
Logistics and Service
Logistics and service drive Enovis cost structure through global warehousing, cold and sterile chain compliance, and centralized inventory and instrument set management to minimize stockouts and obsolescence; field service, repairs, warranty and returns add after-sales labor, spare parts and reverse-logistics expenses that raise total lifecycle costs.
- Cold/sterile chain: regulatory compliance and monitoring
- Inventory: set optimization and obsolescence control
- Field service: technician labor and parts
- Warranty/returns: reverse logistics and refurbishment
FY24 R&D $90M, 18% software, SG&A 20-25%
Enovis cost base centers on FY2024 R&D of ~$90M, with ~18% of R&D toward software/digital health and significant IP/clinical spend. Manufacturing COGS driven by materials, machining, sterilization and QC alongside yield loss and packaging. SG&A ranged 20–25% of revenue in 2024, supported by a 200+ salesforce and distributor margins of 20–30%.
| Line | 2024 |
|---|---|
| R&D | $90M |
| Software R&D | 18% |
| SG&A | 20–25% rev |
| Salesforce | 200+ |
| Distributor margin | 20–30% |
Revenue Streams
Implant Systems
Sales of surgical implants and instruments form a core Enovis revenue stream, with implant systems and instruments driving recurring case-based kit and capital set orders; implant-related products represented roughly 45% of Enovis FY2024 revenue, about $630 million. Upsell opportunities from revisions and add-ons increase average selling price and lifetime value per surgeon, while long-term surgeon loyalty sustains high procedure volume and repeat purchases.
Bracing and Supports
Retail and clinical sales of orthoses drive Enovis bracing revenue across hospitals, ASCs and retail chains, targeting a global orthoses market estimated at about 6.5 billion in 2024.
Product mix includes custom-fitted orthoses and off-the-shelf SKUs to serve post-op, sports and chronic indications, enabling higher margins on custom solutions.
Distribution spans direct-to-consumer e-commerce and clinician channels with significant payer-reimbursed volume for long-term care, supporting repeat purchases for chronic conditions.
Rehab Technologies
Enovis monetizes Rehab Technologies through sales of connected devices and companion recovery and monitoring software, contributing to the company’s FY2024 revenue of about $1.2 billion. Subscription fees for digital tools and clinic/patient licensing create recurring revenue streams, while data-enabled service packages—analytics, remote monitoring, outcomes reporting—sell as premium add-ons. These mixed streams aim to increase recurring revenue and lifetime value per patient.
Consumables and Disposables
Enovis drives recurring revenue through sterile packs, single-use instruments, and accessories that support predictable procedure-level demand and high attach rates; its consumables strategy delivered strong 2024 momentum with consumables and disposables noted as key margin drivers by management.
Bundling consumables with implant cases increases per-procedure revenue and customer lock-in, while margin-accretive add-ons and higher frequency ordering improve gross margins and cash conversion.
- Sterile packs — recurring, procedure-tied demand
- Single-use instruments — high attach rates, infection-control value
- Bundles with implants — increases wallet share per case
- Accessories — margin-accretive, predictable reorder cadence
Service and Training
Service and Training revenue for Enovis bundles clinical education, maintenance and support fees with customization and fitting services, extended warranties and multi-year contracts, and consulting for pathway optimization to drive recurring, higher-margin aftermarket income.
- Clinical education fees
- Maintenance & support
- Customization & fitting
- Extended warranties/contracts
- Consulting for pathway optimization
Implants drove 45% of FY24 revenue; kits enable recurring upsell
Sales of implants/instruments drove ~45% of Enovis FY2024 revenue (~$630M of $1.2B), with case-tied kits and capital sets providing recurring orders and upsell from revisions/add-ons.
Bracing/orthoses mix spans custom and OTS SKUs across hospitals, ASCs and retail; global orthoses market ≈ $6.5B (2024).
Consumables, sterile packs and service/training add recurring, margin-accretive revenue and customer lock-in.
| Metric | 2024 |
|---|---|
| Total revenue | $1.2B |
| Implants | $630M (45%) |
| Orthoses market | $6.5B |